References
- Agarwal, S. D., & Landon, B. E. (2019). Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Network Open, 2(1), e187399-e187399. https://doi.org/https://doi.org/10.1001/jamanetworkopen.2018.7399
- Alex, B., Weiss, D. B., Kaba, F., Rosner, Z., Lee, D., Lim, S., Venters, H., & MacDonald, R. (2017). Death after jail release: Matching to improve care delivery. Journal of Correctional Health Care: The Official Journal of the National Commission on Correctional Health Care, 23(1), 83–87. https://doi.org/https://doi.org/10.1177/1078345816685311
- Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020). Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC). PLoS One, 15(1), e0227966. https://doi.org/https://doi.org/10.1371/journal.pone.0227966
- Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016). Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. American Journal of Public Health, 106(4), 686–688. https://doi.org/https://doi.org/10.2105/AJPH.2016.303061
- Bagley, S. M., Schoenberger, S. F., Waye, K. M., & Walley, A. Y. (2019). A scoping review of post opioid-overdose interventions. Preventive Medicine, 128, 105813. https://doi.org/https://doi.org/10.1016/j.ypmed.2019.105813
- Beletsky, L., LaSalle, L., Newman, M., Paré, J., Tam, J., & Tochka, A. (2015). Fatal re-entry: Legal and programmatic opportunities to curb opioid overdose among individuals newly released from incarceration (SSRN Scholarly Paper ID 2628297). Social Science Research Network. https://papers.ssrn.com/abstract=2628297
- Binswanger, I. A., Blatchford, P. J., Lindsay, R. G., & Stern, M. F. (2011). Risk factors for all-cause, overdose and early deaths after release from prison in Washington state. Drug and Alcohol Dependence, 117(1), 1–6. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2010.11.029
- Binswanger, I. A., Blatchford, P. J., Mueller, S. R., & Stern, M. F. (2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9), 592–600. https://doi.org/https://doi.org/10.7326/0003-4819-159-9-201311050-00005
- Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison-a high risk of death for former inmates. The New England Journal of Medicine, 356(2), 157–165. https://doi.org/https://doi.org/10.1056/NEJMsa064115
- Bohnert, A. S. B., Valenstein, M., Bair, M. J., Ganoczy, D., McCarthy, J. F., Ilgen, M. A., & Blow, F. C. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA, 305(13), 1315–1321. https://doi.org/https://doi.org/10.1001/jama.2011.370
- Bukten, A., Stavseth, M. R., Skurtveit, S., Tverdal, A., Strang, J., & Clausen, T. (2017). High risk of overdose death following release from prison: Variations in mortality during a 15-year observation period. Addiction (Abingdon, England), 112(8), 1432–1439. https://doi.org/https://doi.org/10.1111/add.13803
- Bunting, A. M., Victor, I. I. I., G., Pike, E., Staton, M., Winston, E., & Pangburn, K. (2020). The impact of policy changes on heroin and nonmedical prescription opioid use among an incarcerated population in Kentucky, 2008 to 2016. Criminal Justice Policy Review, 31(5), 746–762. https://doi.org/https://doi.org/10.1177/0887403419838029
- Carroll, J., Rich, J., & Green, T. (2018). The more things change: buprenorphine/naloxone diversion continues while treatment remains inaccessible. Journal of Addiction Medicine, 12(6), 459–465. https://doi.org/https://doi.org/10.1097/ADM.0000000000000436
- Caudarella, A., Dong, H., Milloy, M. J., Kerr, T., Wood, E., & Hayashi, K. (2016). Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug and Alcohol Dependence, 162, 51–55. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2016.02.024
- Centers for Disease Control & Prevention. (2017). Drug overdose mortality by state. https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm
- Chang, D. C., Klimas, J., Wood, E., & Fairbairn, N. (2018). Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions. The American Journal of Drug and Alcohol Abuse, 44(2), 143–146. https://doi.org/https://doi.org/10.1080/00952990.2017.1399403
- Cicero, T. J., Ellis, M. S., & Chilcoat, H. D. (2018). Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence, 193, 117–123. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.09.007
- Cicero, T. J., Kasper, Z. A., & Ellis, M. S. (2018). Increased use of heroin as an initiating opioid of abuse: Further considerations and policy implications. Addictive Behaviors, 87, 267–271. https://doi.org/https://doi.org/10.1016/j.addbeh.2018.05.030
- Court Times. (2017a, February 28). Abstract of judgment data to improve criminal history repository. Indiana Court Times. http://indianacourts.us/times/2017/02/abstract-of-judgment-data-to-improve-criminal-history-repository/
- Court Times. (2017b, October 11). Commitment to data sharing. Indiana Court Times. http://indianacourts.us/times/2017/10/commitment-to-data-sharing/
- Crabtree, A., Lostchuck, E., Chong, M., Shapiro, A., & Slaunwhite, A. (2020). Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in british columbia, canada: CMAJ. Canadian Medical Association. Journal, 192(34), E967-E972.
- Del Pozo, B., & Beletsky, L. (2020). No “back to normal” after COVID-19 for our failed drug policies. The International Journal on Drug Policy, 83, 102901.
- D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial. JAMA, 313(16), 1636–1644. https://doi.org/https://doi.org/10.1001/jama.2015.3474
- Fiscella, K., Beletsky, L., & Wakeman, S. E. (2017). The Inmate Exception and Reform of Correctional Health Care. American Journal of Public Health, 107(3), 384–385. https://doi.org/https://doi.org/10.2105/AJPH.2016.303626
- Fiscella, K., Wakeman, S. E., & Beletsky, L. (2018). Implementing opioid agonist treatment in correctional facilities. JAMA Internal Medicine, 178(9), 1153–1154. https://doi.org/https://doi.org/10.1001/jamainternmed.2018.3504
- Formica, S. W., Apsler, R., Wilkins, L., Ruiz, S., Reilly, B., & Walley, A. Y. (2018). Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts. The International Journal on Drug Policy, 54, 43–50. https://doi.org/https://doi.org/10.1016/j.drugpo.2018.01.001
- Green, T. C., Clarke, J., Brinkley-Rubinstein, L., Marshall, B. D. L., Alexander-Scott, N., Boss, R., & Rich, J. D. (2018). Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry, 75(4), 405–407. https://doi.org/https://doi.org/10.1001/jamapsychiatry.2017.4614
- Greenwald, G. (2009). Drug decriminalization in Portugal: lessons for creating fair and successful drug policies. Cato Institute Whitepaper Series.
- Hirschfeld, P. (2019, March 22). Health experts push to decriminalize addiction treatment drug. https://www.vpr.org/post/health-experts-push-decriminalize-addiction-treatment-drug
- Huynh, P., Victor, G., & Ray, B. (2020). Using prescribing and toxicology data to determine non-medical prescription drug overdose. Addictive Behaviors Reports, 12, 100289https://doi.org/https://doi.org/10.1016/j.abrep.2020.100289
- Indiana State Department of Health. (2019). Drug overdose epidemic in Indiana: Behind the numbers. https://www.in.gov/isdh/files/85_Drug%20Overdose%20Data%20Brief_2019.pdf
- Joudrey, P. J., Khan, M. R., Wang, E. A., Scheidell, J. D., Edelman, E. J., McInnes, D. K., & Fox, A. D. (2019). A conceptual model for understanding post-release opioid-related overdose risk. Addiction Science & Clinical Practice, 14(1), 17.https://doi.org/https://doi.org/10.1186/s13722-019-0145-5
- Krawczyk, N., Schneider, K. E., Eisenberg, M. D., Richards, T. M., Ferris, L., Mojtabai, R., Stuart, E. A., Casey Lyons, B., Jackson, K., Weiner, J. P., & Saloner, B. (2020). Opioid overdose death following criminal justice involvement: Linking statewide corrections and hospital databases to detect individuals at highest risk. Drug Alcohol Depend, 213, 107997. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.107997
- Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. The Lancet, 377(9776), 1506–1513. https://doi.org/https://doi.org/10.1016/S0140-6736(11)60358-9
- Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/https://doi.org/10.7326/M17-3107
- Lim, S., Seligson, A. L., Parvez, F. M., Luther, C. W., Mavinkurve, M. P., Binswanger, I. A., & Kerker, B. D. (2012). Risks of drug-related death, suicide, and homicide during the immediate post-release period among people released from New York City jails, 2001–2005. American Journal of Epidemiology, 175(6), 519–526. https://doi.org/https://doi.org/10.1093/aje/kwr327
- Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., Oosman, S., Peterson, S., Chen, M., & Kim, S. (2018). Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial. JAMA Internal Medicine, 178(6), 764. https://doi.org/https://doi.org/10.1001/jamainternmed.2018.1052
- Lowder, E. M., Amlung, J., & Ray, B. R. (2020). Individual and county-level variation in outcomes following non-fatal opioid-involved overdose. Journal of Epidemiology and Community Health, 2019–212915. https://doi.org/https://doi.org/10.1136/jech-2019-212915
- Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2004). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, 3, CD002207. https://doi.org/https://doi.org/10.1002/14651858.CD002207.pub2
- Mattick, R., Kimber, J., Breen, C., & Davoli, M. (2003). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Library, 2014 (2), CD002207–CD002207. https://doi.org/https://doi.org/10.1002/14651858.CD002207.pub4
- Matusow, H., Dickman, S. L., Rich, J. D., Fong, C., Dumont, D. M., Hardin, C., Marlowe, D., & Rosenblum, A. (2013). Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. Journal of Substance Abuse Treatment, 44(5), 473–480. https://doi.org/https://doi.org/10.1016/j.jsat.2012.10.004
- McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction (Abingdon, England), 111(7), 1177–1187. https://doi.org/https://doi.org/10.1111/add.13326
- McLean, K., & Kavanaugh, P. R. (2019). “They’re making it so hard for people to get help”: Motivations for non-prescribed buprenorphine use in a time of treatment expansion. The International Journal on Drug Policy, 71, 118–124. https://doi.org/https://doi.org/10.1016/j.drugpo.2019.06.019
- Merrall, E. L. C., Kariminia, A., Binswanger, I. A., Hobbs, M. S., Farrell, M., Marsden, J., Hutchinson, S. J., & Bird, S. M. (2010). Meta-analysis of drug-related deaths soon after release from prison: Drug-related deaths after release from prison. Addiction (Abingdon, England), 105(9), 1545–1554. https://doi.org/https://doi.org/10.1111/j.1360-0443.2010.02990.x
- MPH Home—MPH: Management Performance Hub. (n.d.). Retrieved April 2, 2020, from https://www.in.gov/mph/
- Multi-Drug Toxicology Report Summary. (2019). Wayne State School of Social Work, Center for Behavioral Health and Justice. https://www.in.gov/isdh/files/September%202019%20Toxicology%20Report.pdf
- National Sheriffs’ Association, & National Commission on Correctional Health Care. (2018). Jail-Based Medication Assisted Treatment: Promising Practices, Guidelines, and Resources for the Field. https://www.sheriffs.org/publications/Jail-Based-MAT-PPG.pdf
- Nechuta, S. J., Tyndall, B. D., Mukhopadhyay, S., & McPheeters, M. L. (2018). Sociodemographic factors, prescription history and opioid overdose deaths: A statewide analysis using linked PDMP and mortality data. Drug and Alcohol Dependence, 190, 62–71.
- Olfson, M., Wall, M., Wang, S., Crystal, S., & Blanco, C. (2018). Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug and Alcohol Dependence, 190, 112–119. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.06.004
- Paulozzi, L. J., Kilbourne, E. M., & Desai, H. A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine (Malden, Mass.), 12(5), 747–754. https://doi.org/https://doi.org/10.1111/j.1526-4637.2011.01062.x
- Ray, B., Lowder, E., Bailey, K., Huynh, P., Benton, R., & Watson, D. (2020). Racial differences in overdose events and polydrug detection in Indianapolis, Indiana. Drug and Alcohol Dependence, 206, 107658. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2019.107658
- Ray, B., Lowder, E. M., Kivisto, A. J., Phalen, P., & Gil, H. (2018). EMS naloxone administration as non-fatal opioid overdose surveillance: 6-year outcomes in Marion County, Indiana. Addiction (Abingdon, England), 113(12), 2271–2279. https://doi.org/https://doi.org/10.1111/add.14426
- Regenstein, M., & Christie-Maples, J. (2012). Medicaid coverage for individuals in jail pending disposition: Opportunities for improved health and health care at lower costs. Health Policy and Management Faculty Publications. https://hsrc.himmelfarb.gwu.edu/sphhs_policy_facpubs/1
- Reinke, K. (2020, March 3). Boone County Jail becomes first in state to administer suboxone for addiction treatment. Fox 59. https://fox59.com/news/crimetracker/boone-county-jail-becomes-first-in-state-to-administer-suboxone-for-addiction-treatment/
- Rosenthal, E. S., Karchmer, A. W., Theisen-Toupal, J., Castillo, R. A., & Rowley, C. F. (2016). Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis. The American Journal of Medicine, 129(5), 481–485. https://doi.org/https://doi.org/10.1016/j.amjmed.2015.09.024
- Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2018). Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR. Morbidity and Mortality Weekly Report, 67(5152), 1419–1427. https://doi.org/https://doi.org/10.15585/mmwr.mm6751521e1
- Scott, C. K., Grella, C. E., Nicholson, L., & Dennis, M. L. (2018). Opioid recovery initiation: Pilot test of a peer outreach and modified Recovery Management Checkup intervention for out-of-treatment opioid users. Journal of Substance Abuse Treatment, 86, 30–35. https://doi.org/https://doi.org/10.1016/j.jsat.2017.12.007
- Seaman, S. R., Brettle, R. P., & Gore, S. M. (1998). Mortality from overdose among injecting drug users recently released from prison: Database linkage study. BMJ (Clinical Research ed.), 316(7129), 426–428. https://doi.org/https://doi.org/10.1136/bmj.316.7129.426
- Silverstein, S. M., Daniulaityte, R., Miller, S. C., Martins, S. S., & Carlson, R. G. (2020). On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug and Alcohol Dependence, 210, 107958. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.107958
- Shefner, R. T., Sloan, J. S., Sandler, K. R., & Anderson, E. D. (2020). Missed opportunities: Arrest and court touchpoints for individuals who fatally overdosed in philadelphia in 2016. The International Journal of Drug Policy, 78, 102724–102724.
- Smith, K. E., Bunting, A. M., Walker, R., Hall, M. T., Grundmann, O., & Castillo, O. (2019). Non-prescribed buprenorphine use mediates the relationship between heroin use and kratom use among a sample of polysubstance users. Journal of Psychoactive Drugs, 51(4), 311–322. https://doi.org/https://doi.org/10.1080/02791072.2019.1597224
- Smith, K. E., Tillson, M. D., Staton, M., & Winston, E. M. (2020). Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky. Drug and Alcohol Dependence, 208, 107837. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.107837
- Soares, W. E., Wilson, D., Gordon, M. S., Lee, J. D., Nunes, E. V., O’Brien, C. P., Shroff, M., & Friedmann, P. D. (2019). Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug Alcohol Depend, 194, 482–486. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2018.10.035
- Social Security Act Amendments. 1965 of 1965, Pub. L. No. 97, §1396d 42 USC
- Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. https://doi.org/https://doi.org/10.1136/bmj.j1550
- Surratt, H. L., Staton, M., Leukefeld, C. G., Oser, C. B., & Webster, J. M. (2018). Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia. Journal of Addictive Diseases, 37(1–2), 1–4. https://doi.org/https://doi.org/10.1080/10550887.2018.1531738
- Suzuki, J., & El-Haddad, S. (2017). A review: Fentanyl and non-pharmaceutical fentanyls. Drug and Alcohol Dependence, 171, 107–116. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2016.11.033
- Uchtenhagen, A. (2010). Heroin-assisted treatment in Switzerland: a case study in policy change . Addiction (Abingdon, England), 105(1), 29–37. https://doi.org/https://doi.org/10.1111/j.1360-0443.2009.02741.x
- Victor, G., Strickland, J., Kheibari, A., & Flaherty, C. (2020). A mixed-methods approach to understanding overdose risk-management strategies among a nationwide convenience sample. The International Journal on Drug Policy, 86, 102973. https://doi.org/https://doi.org/10.1016/j.drugpo.2020.102973
- Victor, G. A., Walker, R., Cole, J., & Logan, T. K. (2017). Opioid analgesics and heroin: Examining drug misuse trends among a sample of drug treatment clients in Kentucky. International Journal of Drug Policy, 46, 1–6. https://doi.org/https://doi.org/10.1016/j.drugpo.2017.01.008
- Vorspan, F., Hjelmström, P., Simon, N., Benyamina, A., Dervaux, A., Brousse, G., Jamain, T., Kosim, M., & Rolland, B. (2019). What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opinion on Drug Delivery, 16(9), 907–914. https://doi.org/https://doi.org/10.1080/17425247.2019.1649252
- Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), e1920622. https://doi.org/https://doi.org/10.1001/jamanetworkopen.2019.20622
- Wakeman, S. E., McKinney, M. E., & Rich, J. D. (2009). Filling the gap: The importance of Medicaid continuity for former inmates. Journal of General Internal Medicine, 24(7), 860–862. https://doi.org/https://doi.org/10.1007/s11606-009-0977-x
- Wakeman, S. E., & Rich, J. D. (2015). Addiction treatment within U.S. correctional facilities: Bridging the gap between current practice and evidence-based care. Journal of Addictive Diseases, 34(2–3), 220–225. https://doi.org/https://doi.org/10.1080/10550887.2015.1059217
- Walley, A. Y., Doe-Simkins, M., Quinn, E., Pierce, C., Xuan, Z., & Ozonoff, A. (2013). Opioid overdose prevention with intranasal naloxone among people who take methadone. Journal of Substance Abuse Treatment, 44(2), 241–247. https://doi.org/https://doi.org/10.1016/j.jsat.2012.07.004
- Waye, K. M., Goyer, J., Dettor, D., Mahoney, L., Samuels, E. A., Yedinak, J. L., & Marshall, B. D. L. (2019). Implementing peer recovery services for overdose prevention in Rhode Island: An examination of two outreach-based approaches. Addictive Behaviors, 89, 85–91. https://doi.org/https://doi.org/10.1016/j.addbeh.2018.09.027
- Wheeler, E. (2020, January 3). Harm reduction programs distribute one million doses of naloxone in 2019. Medium. https://medium.com/@ejwharmreduction/harm-reduction-programs-distribute-one-million-doses-of-naloxone-in-2019-4884d3535256
- Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. Journal of Neurosciences in Rural Practice, 3(1), 45–50. https://doi.org/https://doi.org/10.4103/0976-3147.91934
- Woolf, S. H., & Schoomaker, H. (2019). Life expectancy and mortality rates in the United States, 1959–2017. JAMA, 322(20), 1996–2016. https://doi.org/https://doi.org/10.1001/jama.2019.16932